Indoco
Indoco Remedies Ltd stock jumps after major nod from US Food and Drug Administration—investors rush in
Mumbai/IBNS: The share prices of Indoco Remedies Ltd. on Tuesday climbed almost 7% after the company received the final Abbreviated New Drug Application (ANDA) from US Food and Drug Administration (USFDA) for Brivaracetam Oral Solution, 10 mg/mL, to market, CNBC TV 18 reported.
Brivaracetam Oral Solution is a generic equivalent to the reference listed drug (RLD), Briviact 10 mg/mL, of UCB, Inc.
The company said in a release that Brivaracetam Oral Solution, 10 mg/mL, has been determined to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Briviact 10 mg/mL of UCB, Inc.
Brivaracetam Oral Solution will be manufactured by Indoco Remedies Limited, at their manufacturing facility located at L-14, Verna Industrial Area, Verna, Goa – 403722 in India.
Brivaracetam Oral Solution (10 mg/mL) is a prescription antiepileptic drug (anticonvulsant) used for treatment of partial-onset seizures in patients 1 month of age and older.
Commenting on the achievement, Aditi Panandikar, Managing Director said, “The ANDA approval for Brivaracetam is a significant milestone for us as we continue to strengthen our presence in the Regulated Markets. We are committed to offering innovative and affordable healthcare to patients worldwide.”
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
